目的 分析2015-2018年浙江省12家医院肿瘤患者抗凝药物的使用现状及其用药特点和趋势。方法 对2015-2018年浙江省12家医院肿瘤患者使用的抗凝药物的用药金额、用药频度（DDDs）、限定日费用（DDC）及排序比（B/A）等情况进行统计分析。结果 2015-2018年肿瘤患者抗凝药物的用药总金额呈上升趋势，2018年比2015年上涨2倍左右；其中肝素类抗凝药的DDDs和DDC排名较前，肝素钠类B/A大于或接近于1，肝素钙类B/A小于1；新型口服抗凝药利伐沙班片、阿哌沙班片和达比加群酯胶囊的DDDs逐年上涨，但排名仍较后，且DDC较高，B/A接近于1；纤溶药的DDDs轻微上升，但DDC较为稳定，B/A小于1；华法林的DDDs稳定，DDC低廉，B/A大于1。结论 2015-2018年浙江省12家医院肿瘤患者抗凝药物的使用基本合理，基本无滥用情况。

Objective To analysis the current situation and the characteristic and tendency of anticoagulants used in cancer patients in Zhejiang Province. Methods The prescriptions data of cancer patients in 12 hospitals of Zhejiang Province from 2015 to 2018 were statistically analyzed, including the consumption, frequency of drug use (DDDs), defined daily cost (DDC) and drug sequence ratio (B/A). Results The consumption of anticoagulants showed an overall increased trend in 2018 compared to 2015 and it increased about twice in 2018 as much as in 2015. DDDs and DDC of heparin anticoagulants ranked higher, and B/A of heparin sodium was larger or close to 1 while the heparin calcium is less than 1. DDDs of the new oral anticoagulants including rivaroxaban, apixaban and dabigatran increased year by year while the ranking were still lower, and DDC was higher, meanwhile B/A were close to 1. DDDs of fibrinolytic drugs slight increased while DDC were stable, and B/A was less than 1. Warfarin has a stable frequency, low daily cost, and B/A were ratio greater than 1. Conclusions The utilization of anticoagulants varieties used by cancer patients was generally reasonable in 12 hospitals of Zhejiang Province from 2015 to 2018, basically no abuse.

R973

浙江省自然科学基金资助项目（LQ15H020001）